Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
NCT ID: NCT00558467
Last Updated: 2014-05-16
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
63 participants
INTERVENTIONAL
2008-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Investigate Pharmacokinetics (PK) of Pramipexole in Pediatric Patients Who Are Individually Optimized to Stable Pramipexole Doses for the Treatment of Idiopathic Restless Legs Syndrome (RLS)
NCT02231918
A Phase IV Trial With Pramipexole to Investigate the Effects on RLS Symptoms and Sleep Disturbance in Patients With RLS
NCT00349531
A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS
NCT00375284
Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS)
NCT00133198
Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1
NCT04886518
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pramipexole
pramipexole immediate release (IR)
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pramipexole immediate release (IR)
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written informed consent.
* Diagnosed with Tourette's Disorder with a \> or equal to 22 on the Total Tic Score at baseline.
* Diagnosed with Tourette's Disorder when administering the Diagnostic Interview Schedule for Children.
* Having at least 1 tic/day.
* Women of childbearing age must have a negative serum pregnancy test at screening and must use a medically accepted contraceptive method.
* Either a newly diagnosed patient or a patient diagnosed with Tourette's Disorder who can safely discontinue treatment.
* Having a body weight of \> or equal to 20 kg (44 lbs).
Exclusion Criteria
* Patients who have clinically significant renal disease or serum creatinine greater than 1.0 mg/dL at screening.
* Lab results at screening: hemoglobin below lower limit of normal which is determined to be clinically significant; Thyroid Stimulating Hormone (TSH), triiodothyronine (T3) or thyroxine (T4) clinically significant; clinically significant abnormalities in labs.
* Other clinically significant metabolic-endocrine, hematological, gastrointestinal disease, pulmonary disease which would preclude the patient from participating in this study.
* History of Schizophrenia or any psychotic disorder, history of mental disorders or any present Axis I psychiatric disorder according to Diagnostic and Statistic Manual of Mental Disorders Fourth Edition (DSM-IV) requiring any medical therapy except for patients with a diagnosis of attention deficit hyperactivity disorder (ADHD) or obsessive-compulsive disorder (OCD) who are not on therapy.
* History of/or clinical signs of epilepsy or seizures other than fever related seizures in early childhood.
* History of/or clinical signs of any malignant neoplasm.
* Allergic response to pramipexole.
* Had previous treatment with dopamine agonists other than pramipexole within 14 days prior to baseline visit.
* Had any other medical treatment for Tourette's Disorder besides the study medication within 28 days prior to baseline visit.
* Had withdrawal symptoms of any medication at screening or at the baseline visit.
* Having a Kaufman Brief Intelligence Test (KBIT IQ) score \<70 at screening.
* Having a children's Yale-Brown obsessive-compulsive scale (CY-BOCS) score of \>15 at baseline.
* Patients who meet criteria for Restless Legs Syndrome and or Periodic Limb Movement disorder.
* Patients with severe asthma.
* Patients that have initiated psychotherapy for Tourette's Disorder, OCD or ADHD within 3 mths of starting the trial.
* Patients receiving psychological, cognitive and/or behavioral treatments greater than 3 mths prior to start of trial for Tourette's Disorder, OCD, and/or ADHD who will have changes in treatment plan.
6 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Boehringer Ingelheim
Role: STUDY_CHAIR
Boehringer Ingelheim
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
248.644.0026 Boehringer Ingelheim Investigational Site
Bradenton, Florida, United States
248.644.0025 Boehringer Ingelheim Investigational Site
Tampa, Florida, United States
248.644.0006 Boehringer Ingelheim Investigational Site
Columbus, Georgia, United States
248.644.0012 Boehringer Ingelheim Investigational Site
Chicago, Illinois, United States
248.644.0005 Boehringer Ingelheim Investigational Site
Cambridge, Massachusetts, United States
248.644.0003 Boehringer Ingelheim Investigational Site
Manhasset, New York, United States
248.644.0009 Boehringer Ingelheim Investigational Site
New York, New York, United States
248.644.0018 Boehringer Ingelheim Investigational Site
New York, New York, United States
248.644.0013 Boehringer Ingelheim Investigational Site
Orangeburg, New York, United States
248.644.0029 Boehringer Ingelheim Investigational Site
Oklahoma City, Oklahoma, United States
248.644.0010 Boehringer Ingelheim Investigational Site
Providence, Rhode Island, United States
248.644.0030 Boehringer Ingelheim Investigational Site
Memphis, Tennessee, United States
248.644.0008 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
248.644.0023 Boehringer Ingelheim Investigational Site
Norfolk, Virginia, United States
248.644.49001 Boehringer Ingelheim Investigational Site
Hanover, , Germany
248.644.49004 Boehringer Ingelheim Investigational Site
Ulm, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
248.644
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.